Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.
Prime Medicine Inc.
(NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc.
(NASDAQ:BEAM).
The tribunal on Wednesday determined that Prime Medicine's investigational gene-editing therapy PM647 falls within the scope of the companies' 2019 Collaboration and License Agreement.
The decision clears the company of any breach of contract claims and eliminates any financial liability related to the case.
Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed…
Prime Medicine wins arbitration vs Beam Therapeutics, plans FDA IND filing for genetic liver disease treatment. $PRME stock rises…
AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent…
Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint…
Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
Prime Medicine wins spat with Beam Therapeutics over AATD candidate
Prime wins Beam arbitration, clearing path to clinic
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
